Current Affairs - International - Discussion

The United States has taken a major step in integrating artificial intelligence into healthcare regulation through its Food and Drug Administration (FDA). The FDA qualified AIM-NASH, the first AI-powered tool designed to assist in assessing severe fatty liver disease during drug trials. This qualification enables faster, more consistent evaluation of liver biopsy data, helping reduce delays, variability, and costs in clinical research. By supporting the development of treatments for metabolic dysfunction-associated steatohepatitis (MASH), the decision highlights the growing role of AI in modern drug development and reflects strong regulatory confidence in AI-assisted diagnostics.